<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895204</url>
  </required_header>
  <id_info>
    <org_study_id>SU_immune</org_study_id>
    <nct_id>NCT02895204</nct_id>
  </id_info>
  <brief_title>Effect of Fermented Maillard Reacted Whey Protein on Immune Function</brief_title>
  <official_title>The Immune-enhancing Effect of Supplementation With Fermented Maillard Reacted Whey Protein in Nondiabetic and Nonobese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <brief_summary>
    <textblock>
      To investigate the impact of supplementing fermented Maillard reacted whey protein (F-MRP) on
      natural killer (NK) cell activity, circulating cytokines and serum protein levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled study was conducted on 80 participant without
      diabetes and obesity. Over a 8-week testing period, the F-MRP group consumed 6 g of powder
      containing 4.2 g F-MRP each day, whereas the placebo group consumed the same amount with
      dextrin. NK cell activity (%) was measured based on the ratios of effector cells (E;
      peripheral blood mononuclear cells, PBMCs) from each participant to target cells (T; K562
      cells) at E:T= 10:1, 5:1, 2.5:1, or 1.25:1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Natural killer cell activity</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Natural killer cell activity</measure>
    <time_frame>At 8-week follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline natural killer cell activity at 8-week</measure>
    <time_frame>At baseline and 8-week follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>White blood cell</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell</measure>
    <time_frame>At 8-week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline white blood cell at 8-week</measure>
    <time_frame>At baseline and 8-week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-12</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-12</measure>
    <time_frame>At 8-week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Interleukin-12 at 8-week</measure>
    <time_frame>At baseline and 8-week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-gamma</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-gamma</measure>
    <time_frame>At 8-week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Interferon-gamma at 8-week</measure>
    <time_frame>At baseline and 8-week follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Test group (F-MRP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fermented Maillard reacted whey protein (F-MRP) supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fermented Maillard reacted whey protein (F-MRP)</intervention_name>
    <description>6g of powder containing 4.2g fermented maillard reacted whey protein</description>
    <arm_group_label>Test group (F-MRP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6g of maltodextrin</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to give informed consent

          -  The levels of white blood cells within range 3x10^3/μL~8x10^3/μL

          -  Males and females

          -  20-70 years old

          -  Without no severe complications

        Exclusion Criteria:

          -  Diabetes

          -  White blood cell under 3x10^3/μL or over 8x10^3/μL

          -  Pregnancy or breast-feeding

          -  Hypersensitivity or disease history for milk protein

          -  Liver disease, inflammation disease, or severe kidney failure disease

          -  Cancer, lung disease, leukemia, or autoimmune disease

          -  Psychological or neurological disease

          -  Myocardiac infarction or cerebrovascular diseases within 6 months before screening

          -  Consumption of other test products or drugs within 1 month before screening

          -  Inflammation related disease within 1 month before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Ho Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fermented Maillard reacted whey protein</keyword>
  <keyword>Natural killer cell activity</keyword>
  <keyword>Immune function</keyword>
  <keyword>Pre-albumin</keyword>
  <keyword>Interleukin-12</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

